Compare Appian Corp (APPN) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Appian Corp vs Moderna, Inc. — how do they compare? Appian Corp trades at $34.48 (market cap $2.54B), while Moderna, Inc. trades at $63.81 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 9.5× Appian Corp's market cap, and Moderna, Inc. is trading nearer its 52-week high, Appian Corp nearer its low. Which is the better fit depends on your goals.
| APPN | MRNA | |
|---|---|---|
Market Cap | $2.54B | $24.18B |
Sector | Technology | Health |
52-Week High | $45.64 | $81.80 |
52-Week Low | $18.72 | $22.36 |
Enterprise Value | $2.67B | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Appian Corporation (APPN) trades at $35.05, down 1.49% on the day, following a series of recent earnings beats. The stock exhibits a bullish technical trend with strong moving average support, though oscillators signal overbought conditions. Fundamentally, the company shows robust revenue growth, reaching $727 million in 2025, and has achieved positive net income after years of losses, yet maintains a negative shareholder equity position. Recent news highlights strategic AI partnerships and strong quarterly performance.
The outlook is cautiously optimistic, driven by AI-driven demand and enterprise growth, but significant risks persist, including high valuation multiples, negative equity, and intense competition. Analyst consensus is mixed, with a majority Hold rating, suggesting the stock may be fully valued near-term despite operational improvements.
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
